Sanofi US - Type 2 Inflammation

For US residents only

Because of the
Common Underlying
Pathology, Many People
Can Have More Than 1
of These Diseases¹

Data from patient registry or cross-sectional study.^2-4

^aAge groups assessed included adults for atopic dermatitis and CRSwNP and adolescents (12-17 years) and adults for asthma.^2-4

^bOther diseases driven by Type 2 inflammation include allergic rhinitis, chronic spontaneous urticaria, and eosinophilic esophagitis.¹

^cSeverity of coexisting diseases was not reported.

^dCoexisting diseases were based on self-reporting of a diagnosis confirmed by a healthcare provider.²

CRSwNP=chronic rhinosinusitis with nasal polyposis.

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of Type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
Simpson E, Guttman-Yassky E, Margolis DJ, et al. Chronicity, comorbidity, and life course impairment in atopic dermatitis: insights from a cross-sectional study in US adults. Poster presented at: 25th European Academy of Dermatology and Venereology; September 28–October 2, 2016; Vienna, Austria.
Heffler E, Blasi F, Latorre M, et al; for the SANI Network. The Severe Asthma Network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7(5):1462-1468.
Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.

IMM.20.10.0003 Last Update: [12/20]